Kymera Therapeutics, Inc. (KYMR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Kymera Therapeutics, Inc. (KYMR) closed at USD 106.83 on 2026-10-14, a change of +72.4 % over the past year, with a market capitalization of USD 8.99B.

Kymera Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kymera Therapeutics, Inc. key figures

Previous close

USD 106.83 (2026-10-14)

1-year change

+72.4 %

Market cap

USD 8.99B

Enterprise value

USD 8.38B

P/E ratio (trailing)

-32.87

P/E ratio (forward)

-21.22

EPS (trailing)

-3.29

EPS (forward)

-5.10

PEG ratio

n/a

Price to book

5.93

Revenue growth

466.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.18

Employees

273

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kymera Therapeutics, Inc. and compare it with other stocks.